Neisvac-C (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid)

• Neisvac‑C is used to induce immunity against meningococcal disease caused by serogroup C.
• Invasive meningococcal disease (serogroup C): induces protective antibodies that prevent infection.
• Meningococcal carriage in adolescents: reduces nasopharyngeal carriage and limits transmission.
• Outbreak response in high‑risk settings: provides rapid immunization to control spread of serogroup C disease.

• Neisvac‑C contains polysaccharide from Neisseria meningitidis group C chemically linked to tetanus toxoid, forming a conjugate that elicits a T‑cell‑dependent immune response. The protein carrier enhances recognition by antigen‑presenting cells, leading to robust B‑cell activation and high‑affinity IgG antibody production against the capsular polysaccharide, thereby providing long‑lasting protection against serogroup C meningococcal infection.

Common and serious adverse reactions have been reported following administration of Neisvac‑C.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Redness or swelling: localized erythema or edema.
• Fever: transient low‑grade fever within 24‑48 hours.
• Headache: mild headache reported post‑vaccination.
• Fatigue: temporary feeling of tiredness.
• Myalgia: muscle aches around the injection area.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Guillain‑Barré syndrome: rare neurological disorder with muscle weakness.
• Seizures: infrequent occurrence, especially in febrile infants.
• Hypotension: sudden drop in blood pressure after injection.
• Severe local reaction: extensive swelling or necrosis at the site.

Before administering Neisvac‑C, consider the following precautions and warnings.

• Allergy assessment: avoid use in individuals with a known severe hypersensitivity to any vaccine component or tetanus toxoid.
• Acute illness: postpone vaccination in persons with moderate or severe febrile illness until recovery.
• Immunocompromised patients: vaccine may elicit reduced immune response; assess benefit‑risk.
• Pregnancy and lactation: safety has not been established; use only if potential benefit justifies the potential risk.
• Age considerations: approved for use in individuals aged 2 years and older; follow local immunization schedules.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Neisvac‑C may interact with other agents that affect immune function or vaccine efficacy.

Major Interactions (Avoid)

• Concurrent administration of other meningococcal conjugate vaccines: may lead to immune interference and reduced antibody response.
• Live vaccines given within 4 weeks: may compromise immune response to either vaccine.

Moderate Interactions (Monitor Closely)

• Immunoglobulin or blood products given within 3 weeks: can diminish vaccine‑induced antibody levels.
• Immunosuppressive therapy: may lower immunogenicity, requiring assessment of protective titers.
• Antipyretics taken prophylactically: may slightly reduce antibody response; advise use only for symptom relief.